DO 2 = oxygen delivery; SvO 2 = mixed venous oxygen saturation; VO 2 = oxygen consumption.
Introduction
Sepsis is associated with systemic, mediator-induced alterations in oxygen utilization, including increased oxygen demand, altered oxygen extraction, and decreased myocardial contractility (Fig. 1) . Hence, despite a normal or high cardiac output, severe sepsis and septic shock are characterized by an inadequate organ oxygenation, leading ultimately to multiple organ failure and death. Almost 20 years ago, Abraham and colleagues [1] noted that survivors from septic shock had significantly higher cardiac indexes prior to the shock episode than did nonsurvivors, leading to the suggestion that pushing patients to reach high and even 'supranormal' levels of cardiac output could be beneficial. This early hypothesis has fueled an ongoing debate regarding the potential benefit or harm of this strategy in the patient with septic shock.
The 'supranormal' studies
Several groups have indicated increased survival in various groups of patients treated with a strategy to increase cardiac output or oxygen delivery (DO 2 ) to so-called 'supranormal' values (cardiac index ≥ 4.5 l/min per m 2 , DO 2 < 600 ml/min per m 2 and oxygen consumption [VO 2 ] >170 ml/min per m 2 ) [2] [3] [4] [5] [6] [7] [8] [9] . However, two notable studies conducted in mixed groups of critically ill patients by Hayes and coworkers [10] and Gattinoni and coworkers [11] showed that supranormal DO 2 values do not result in improved outcomes. A possible explanation for those findings is that, unlike many of the other studies in this field, the heterogeneity of the critically ill patients included in the studies influenced the results. Thus, although some individuals might well have benefited from the trial strategy, these positive results may have been negated by harmful effects in other patients who perhaps had already been adequately resuscitated and therefore received excessive doses of vasopressor agents or fluids. There is little doubt that, in certain patients, achieving and maintaining high levels of cardiac output is associated with improved outcomes; the difficulty lies in identifying those patients.
Should we maintain adequate cardiac output in all patients with septic shock?
coworkers [6] suggested that survivors from septic shock are characterized by an ability to increase DO 2 and VO 2 , whereas nonsurvivors do not have sufficient physiologic reserve to do this, and in such patients excessive doses of vasopressors or fluids worsen an already bad situation. Rather than making attempts to target cardiac output and DO 2 randomly in all patients, our approach should rather be to try to restore hemodynamic stability, which will necessitate different approaches in different patients. Indeed, no one would dispute the need for clinical interventions to enhance DO 2 and support the circulation where tissue perfusion is clearly inadequate. The problem lies in identifying those patients in whom tissue hypoxia is less overt, who may in fact have 'normal' hemodynamic parameters, and augmenting DO 2 in such patients may necessitate reaching 'supranormal' values.
So, how can we determine which patients require what therapy? Perhaps the mixed venous oxygen saturation (SvO 2 ) is the most important parameter to follow. SvO 2 provides an indication of the degree of oxygen extracted by the organs before the blood returns to the right heart and hence gives a measure of the balance between DO 2 and VO 2 , thus providing an indication of the ability of the cardiac output to meet the individual's oxygenation needs. Admittedly, SvO 2 is a global parameter and gives no specific regional information, but neither does cardiac output; in fact, it may be interesting to combine SvO 2 and cardiac output (Fig. 2) . Indeed, this is one of the problems with the less invasive methods of measuring cardiac output; we are all agreed that 'less invasive' is the way to go, but how does one interpret cardiac output values without knowledge of the SvO 2 ? Some may say that SvO 2 monitoring is useless in sepsis or septic shock because, in sepsis, SvO 2 may be normal or high despite regional tissue hypoxia, because of altered tissue oxygen extraction. However, clinical evidence shows that SvO 2 does fluctuate in patients with sepsis or septic shock [12] , and there are two major arguments in support of the value of SvO 2 monitoring in sepsis. First, Ronco and coworkers [13] noted that patients who are about to die may still have high oxygen extraction capabilities. Hence, in septic shock, a high or normal SvO 2 does not necessarily mean that oxygen extraction cannot increase further. Second, Rivers and coworkers [14] showed, in a patient population treated in an emergency department, that the initial central venous oxygen saturation (measured as a substitute for SvO 2 ) was only 48.6 ± 11.2%. Hence, it is only after initial resuscitation that central venous oxygen saturation (or SvO 2 ) may reach normal (or supranormal) values. Conversely, it may decrease again if there is hypovolemia or myocardial depression. Importantly, it is not necessary to calculate DO 2 . Moreover, the relationship between VO 2 and DO 2 is subject to mathematical coupling of data. In complex cases, the relation between cardiac index and oxygen extraction ratio may be helpful, especially in anemia [15, 16] . Finally, blood lactate levels may help to identify the patient who requires a higher cardiac output because survivors from septic shock have significantly lower initial blood lactate levels and their blood lactate levels are raised for shorter periods of time [17] .
Another important feature may be the timing of optimization. In the early studies conducted by Shoemaker and coworkers [2] that showed improved outcome in surgical patients, optimization was commenced before the surgical procedure. Rivers and coworkers [14] recently showed the beneficial effects of early goal-directed therapy, within 6 hours of diagnosis of septic shock, over standard therapy. The methods for increasing cardiac output or DO 2 (e.g. fluids, inotropes, and blood transfusions) may also impact on results. 
Conclusion
More important than achieving supranormal DO 2 and, hence, oxygen consumption in those patients who may benefit from this strategy is achieving optimal hemodynamic status in all patients (Fig. 3) . If augmentation of DO 2 is associated with a reduction in serum lactate levels and improved target organ perfusion, then these interventions may be continued. Each patient must be assessed according to their clinical (urine output, skin perfusion, mental status), hemodynamic (arterial pressure, cardiac output), and oxygenation (SvO 2 , blood lactate) parameters. Practising good medicine is never simple, and applying protocols to reach supranormal DO 2 in all patients is naïve. The challenge is to identify which approach is needed in which patient so that all patients receive optimal care. 
